Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients

Ritonavir-boosted saquinavir (SQV/r) is currently licensed as a twice-daily regimen. Reducing the pill burden with once-daily dosing may improve adherence. Intracellular concentrations of drugs must be related to the clinical efficacy of protease inhibitors. The aims of the study were to determine t...

Full description

Saved in:
Bibliographic Details
Main Authors: Ford, Jennifer, Boffito, Marta, Wildfire, Adrian, Hill, Andrew, Back, David, Khoo, Saye, Nelson, Mark, Moyle, Graeme, Gazzard, Brian, Pozniak, Anton
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2004
Subjects:
Antiviral Agents
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC434222/
https://ncbi.nlm.nih.gov/pubmed/15215085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.7.2388-2393.2004
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items